Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Three-independent cohort, Open-label, Two-period, Sequential Study to Assess Pharmacokinetics of Colchicine Oral Solution in Healthy Adult Subjects

Trial Profile

Three-independent cohort, Open-label, Two-period, Sequential Study to Assess Pharmacokinetics of Colchicine Oral Solution in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Colchicine (Primary) ; Amlodipine; Carvedilol; Ciprofloxacin; Posaconazole
  • Indications Gout
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 29 Aug 2024 According to a Scilex Holding media release, company announced FDA approval of a Supplemental New Drug Application for Label Updates to GLOPERBA.
  • 20 Oct 2020 New trial record
  • 23 Sep 2020 Results assessing effects of carvedilol phosphate on the pharmacokinetics of colchicine oral solution in healthy adult subjects, presented at the 2020 American College of Clinical Pharmacology Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top